Tc 99m HL 91

Drug Profile

Tc 99m HL 91

Alternative Names: 99mTc-HL-91; Prognox

Latest Information Update: 11 Sep 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amersham
  • Class Organotechnetium compounds; Oximes; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 11 Sep 2006 Discontinued - Phase-II for Solid tumours (diagnosis) in Norway (unspecified route)
  • 15 Oct 2003 No development reported - Phase-II for Solid tumours (diagnosis) in Norway (unspecified route)
  • 21 Feb 2001 A study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top